127 related articles for article (PubMed ID: 2935105)
1. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis.
Pizzo SV; Fuchs HE; Doman KA; Petruska DB; Berger H
Arch Intern Med; 1986 Jan; 146(1):188-91. PubMed ID: 2935105
[TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
4. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.
Suffredini AF; Harpel PC; Parrillo JE
N Engl J Med; 1989 May; 320(18):1165-72. PubMed ID: 2496309
[TBL] [Abstract][Full Text] [Related]
5. [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value].
Korninger C
Wien Klin Wochenschr; 1985 Nov; 97(22):832-40. PubMed ID: 2934899
[TBL] [Abstract][Full Text] [Related]
6. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Francis RB; McGehee WG; Feinstein DI
Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
[TBL] [Abstract][Full Text] [Related]
7. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
9. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
10. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
Hamsten A; Wiman B; de Faire U; Blombäck M
N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
[TBL] [Abstract][Full Text] [Related]
12. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator.
Pizzo SV; Murray JC; Gonias SL
Arch Pathol Lab Med; 1986 Jun; 110(6):517-9. PubMed ID: 3085632
[TBL] [Abstract][Full Text] [Related]
13. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
14. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
Colucci M; Paramo JA; Stassen JM; Collen D
J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
[TBL] [Abstract][Full Text] [Related]
15. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.
Kluft C; Verheijen JH; Jie AF; Rijken DC; Preston FE; Sue-Ling HM; Jespersen J; Aasen AO
Scand J Clin Lab Invest; 1985 Nov; 45(7):605-10. PubMed ID: 3934744
[TBL] [Abstract][Full Text] [Related]
16. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
17. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis after application of a pneumatic tourniquet.
Petäjä J; Myllynen P; Myllylä G; Vahtera E
Acta Chir Scand; 1987; 153(11-12):647-51. PubMed ID: 3124428
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
20. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
